Face-to-face Versus Online Hypnotherapy for the Treatment of Irritable Bowel Syndrome
NCT ID: NCT03899779
Last Updated: 2025-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
282 participants
INTERVENTIONAL
2019-07-08
2025-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Hypnotherapy in Irritable Bowel Syndrome (IBS)
NCT01279382
Effect of Hypnotherapy and Educational Intervention in Irritable Bowel Syndrome
NCT01815164
Individual vs. Group Hypnotherapy in Patients With Irritable Bowel Syndrome
NCT03432078
Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)
NCT06297785
A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome
NCT00368771
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Face-to-face hypnotherapy
12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
Face-to-face hypnotherapy
12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
Online hypnotherapy
12 weeks treatment with online hypnotherapy
Online hypnotherapy
12 weeks treatment with online hypnotherapy
Online psychoeducation
12 weeks treatment with online psychoeducation
Online psychoeducation
12 weeks treatment with online psychoeducation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Face-to-face hypnotherapy
12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
Online hypnotherapy
12 weeks treatment with online hypnotherapy
Online psychoeducation
12 weeks treatment with online psychoeducation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of IBS according to the Rome IV criteria
* In the presence of alarm symptoms, such as rectal blood loss, weight loss, anemia, first onset of symptoms above 50 years of age, patients will be first referred for further investigation by their treating physician to exclude organic disorders, conform current Dutch guidelines for IBS.
* Women in fertile age must use contraception or be postmenopausal for at least two years.
Exclusion Criteria
* No access to internet
* Evidence of current anxiety and/or depression disorder as defined by a score ≥10 on the GAD-7 and/or PHQ-9 questionnaire. In this case it is conceivable that the IBS symptoms are strongly related to psychopathology for which different treatment might be more appropriate.
* History of ulcerative colitis, Crohn's disease, coeliac disease or significant liver disease
* Major surgery to the lower gastrointestinal tract, such as partial or total colectomy, small bowel resection or partial or total gastrectomy
* Past or present radiotherapy to the abdomen
* Current pregnancy or lactation
* Using of psychoactive medication in case there's no stable dose for at least 3 months prior to inclusion
* Use of over-the-counter or prescription antidiarrheals, analgesics and laxatives (only be allowed as specific rescue medication)
* Hypnotherapy treatment received in the last 3 months prior to inclusion
* Using more than 20 units of alcohol per week
* Using drugs of abuse
16 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Keszthelyi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Maastricht University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gelderse Vallei
Ede, Gelderland, Netherlands
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, North Brabant, Netherlands
Bernhoven
Uden, North Brabant, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Provincie Friesland, Netherlands
Martini Ziekenhuis
Groningen, Provincie Groningen, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
852001924
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
METC18-037
Identifier Type: OTHER
Identifier Source: secondary_id
NL67607.068.18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.